Your browser doesn't support javascript.
loading
Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy / Avaliação dos níveis de enzima ubiquitina C-terminal hidrolase-L1 em pacientes com epilepsia
Yasak, Ibrahim Halil; Yilmaz, Mustafa; Gonen, Murat; Atescelik, Metin; Gurger, Mehtap; Ilhan, Nevin; Goktekin, Mehmet Cagri.
  • Yasak, Ibrahim Halil; Harran University. Emergency Deparment of Medicine. Sanliurfa. TR
  • Yilmaz, Mustafa; University of Firat. Emergency Medicine. Elazig. TR
  • Gonen, Murat; Firat Universitesi. Tip Fakultesi. Neurology. Elazig. TR
  • Atescelik, Metin; University of Firat. Emergency Medicine. Elazig. TR
  • Gurger, Mehtap; University of Firat. Emergency Medicine. Elazig. TR
  • Ilhan, Nevin; Firat Universitesi. Biochemistry Department. Elazig. TR
  • Goktekin, Mehmet Cagri; University of Firat. Emergency Medicine. Elazig. TR
Arq. neuropsiquiatr ; 78(7): 424-429, July 2020. tab, graf
Article in English | LILACS | ID: biblio-1131727
ABSTRACT
ABSTRACT

Objective:

Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) enzyme levels were investigated in patients with epilepsy, epileptic seizure, remission period, and healthy individuals.

Methods:

Three main groups were evaluated, including epileptic seizure, patients with epilepsy in the non-seizure period, and healthy volunteers. The patients having a seizure in the Emergency department or brought by a postictal confusion were included in the epileptic attack group. The patients having a seizure attack or presenting to the Neurology outpatient department for follow up were included in the non-seizure (remission period) group.

Results:

The UCH-L1 enzyme levels of 160 patients with epilepsy (80 patients with epileptic attack and 80 patients with epilepsy in the non-seizure period) and 100 healthy volunteers were compared. Whereas the UCH-L1 enzyme levels were 8.30 (IQR=6.57‒11.40) ng/mL in all patients with epilepsy, they were detected as 3.90 (IQR=3.31‒7.22) ng/mL in healthy volunteers, and significantly increased in numbers for those with epilepsy (p<0.001). However, whereas the UCH-L1 levels were 8.50 (IQR=6.93‒11.16) ng/mL in the patients with epileptic seizures, they were 8.10 (IQR=6.22‒11.93) ng/mL in the non-seizure period, and no significant difference was detected (p=0.6123). When the UCH-L1 cut-off value was taken as 4.34 mg/mL in Receiver Operating Characteristic (ROC) Curve analysis, the sensitivity and specificity detected were 93.75 and 66.00%, respectively (AUG=0.801; p<0.0001; 95%CI 0.747‒0.848) for patients with epilepsy.

Conclusion:

Even though UCH-L1 levels significantly increased more in patients with epilepsy than in healthy individuals, there was no difference between epileptic seizure and non-seizure periods.
RESUMO
RESUMO

Objetivo:

Níveis da enzima ubiquitina C-terminal hidrolase-L1 (UCH-L1) foram investigados em pacientes com epilepsia, crise epiléptica, período de remissão e indivíduos saudáveis.

Método:

Foram avaliados três grupos principais, incluindo crise epiléptica, epilepsia no período não convulsivo e voluntários saudáveis. Pacientes com convulsão no departamento de emergência ou trazidos por confusão pós-ictal foram incluídos no grupo de crise epiléptica. Os pacientes que tiveram crise epiléptica ou foram ao ambulatório de Neurologia para acompanhamento foram incluídos no grupo não convulsivo (período de remissão).

Resultados:

Os níveis da enzima UCH-L1 de 160 pacientes com epilepsia (80 pacientes com crise epiléptica e 80 pacientes com epilepsia no período não convulsivo) e 100 voluntários saudáveis foram comparados. Enquanto os níveis da enzima UCH-L1 foram 8,30 (IQR=6,57‒11,40) ng/mL em todos os pacientes com epilepsia, os níveis detectados foram de 3,90 (IQR=3,31‒7,22) ng/mL em voluntários saudáveis e aumentaram significativamente na epilepsia (p<0,001). No entanto, ao passo que os níveis de UCH-L1 foram 8,50 (IQR=6,93‒11,16) ng/mL nos pacientes com crise epiléptica, foram 8,10 (IQR=6,22‒11,93) ng/mL no período não convulsivo, e nenhuma diferença significativa foi detectada (p=0,6123). Quando o valor de corte de UCH-L1 foi considerado 4,34 mg/mL com base na análise da curva ROC, sensibilidade e especificidade foram detectadas como 93,75 e 66,00%, respectivamente (AUG=0,801; p<0,0001; IC95% 0,747‒0,848) para os pacientes com epilepsia.

Conclusão:

Embora os níveis de UCH-L1 tenham aumentado significativamente nos pacientes com epilepsia em relação aos indivíduos saudáveis, não foi observada diferença entre crise epiléptica e períodos não convulsivos.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Seizures / Ubiquitin Thiolesterase / Epilepsy Type of study: Diagnostic study / Evaluation studies / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2020 Type: Article Affiliation country: Turkey Institution/Affiliation country: Firat Universitesi/TR / Harran University/TR / University of Firat/TR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Seizures / Ubiquitin Thiolesterase / Epilepsy Type of study: Diagnostic study / Evaluation studies / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2020 Type: Article Affiliation country: Turkey Institution/Affiliation country: Firat Universitesi/TR / Harran University/TR / University of Firat/TR